A Randomized, Open-Label, Parallel-Arm, Optimal Dose-Titration, Multicenter Study to Evaluate the Safety and Efficacy of Oral JNS024 Extended Release (ER) in Japanese Subjects Treated With Around-the-Clock Opioid Analgesics for Their Moderate to Severe Chronic Malignant Tumor- Related Cancer Pain.
Phase of Trial: Phase III
Latest Information Update: 17 Nov 2016
At a glance
- Drugs Tapentadol (Primary) ; Morphine
- Indications Cancer pain
- Focus Therapeutic Use
- 17 Nov 2016 Results of a pooled analysis from this and 6 other trials published in the Annals of the Rheumatic Diseases
- 23 Jan 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 23 Jan 2012 Planned end date changed from 1 Feb 2012 to 1 Jan 2012 as reported by ClinicalTrials.gov.